Skip to main content

Table 2 Longitudinal changes in CVD risk factors and RA disease activity according to treatment group

From: Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis

  csDMARDs TNFi
Baseline 12 months P-value Baseline 12 months P-value
Cardiovascular disease risk factors
 TGL 123 (68) 114 (50) <0.001 113 (48) 106 (46) 0.023
 LDL 122 (32) 112 (19) <0.001 125 (26) 126 (30) 0.535
 HDL 69 (12) 66 (10) <0.001 74 (22) 74 (19) 0.609
 TC 212 (3) 200 (19) <0.001 221 (30) 218 (38) 0.161
 SFG 88 (8) 85 (15) <0.001 94 (13) 91 (11) 0.001
 SBP 130 (19) 135 (19) <0.001 136 (19) 135 (21) 0.152
 DBP 80 (10) 83 (11) <0.001 86 (10) 82 (10) <0.001
 BMI 25.5 (4.5) 25.5 (4.5) 0.442 25.6 (4.1) 25.6 (4.1) 0.226
Rheumatoid arthritis disease activity
 ESR 20 (20) 16 (17) <0.001 20 (17) 19 (14) 0.001
 CRP 5.7 (8.2) 4.6 (8.7) <0.001 2.40 (2.51) 2.49 (2.15) 0.410
 CDAI 10 (10) 10 (10) 0.173 9 (7) 11 (10) <0.001
 DAS28 2.05 (1.35) 2.54 (1.36) 0.002 2.64 (0.77) 2.81 (1.23) 0.108
  1. AoSI, aortic stiffness index; BMI, body mass index, CDAI, clinical disease activity score index; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; DAS28, disease activity score-28; DBP, diastolic blood pressure; ESR, erythrocyte sedimentation rate; HDL; high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; SFG, serum fasting glucose; TC, total cholesterol; TGL, triglycerides; TNFi, tumour necrosis factor inhibitors. All data reported as mean (standard deviation). P-value refers to paired samples t-test comparisons between values at baseline and 12 months